Bingham Osborn & Scarborough LLC bought a new stake in shares of Eli Lilly And Co (NYSE:LLY) in the third quarter, Holdings Channel.com reports. The institutional investor bought 1,816 shares of the company’s stock, valued at approximately $203,000.
A number of other large investors have also recently bought and sold shares of LLY. Selective Wealth Management Inc. purchased a new stake in Eli Lilly And Co during the third quarter valued at approximately $25,000. Enterprise Trust & Investment Co purchased a new stake in Eli Lilly And Co during the third quarter valued at approximately $27,000. Garrett Wealth Advisory Group LLC purchased a new stake in Eli Lilly And Co during the third quarter valued at approximately $29,000. Candriam Luxembourg S.C.A. lifted its position in Eli Lilly And Co by 47.7% during the third quarter. Candriam Luxembourg S.C.A. now owns 270,304 shares of the company’s stock valued at $30,000 after acquiring an additional 87,250 shares during the last quarter. Finally, Prestige Wealth Management Group LLC purchased a new stake in Eli Lilly And Co during the second quarter valued at approximately $34,000. 77.22% of the stock is owned by institutional investors.
LLY has been the subject of a number of research analyst reports. Bank of America initiated coverage on shares of Eli Lilly And Co in a report on Wednesday, October 16th. They issued a “buy” rating and a $133.00 price target for the company. UBS Group decreased their price target on shares of Eli Lilly And Co from $134.00 to $133.00 and set a “buy” rating for the company in a report on Thursday, October 17th. Six equities research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company. The company currently has an average rating of “Buy” and an average price target of $130.03.
In other news, SVP Alfonso G. Zulueta sold 19,500 shares of the stock in a transaction on Tuesday, September 3rd. The shares were sold at an average price of $112.91, for a total value of $2,201,745.00. Following the sale, the senior vice president now owns 38,306 shares in the company, valued at $4,325,130.46. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, major shareholder Lilly Endowment Inc sold 210,000 shares of the stock in a transaction on Friday, September 20th. The stock was sold at an average price of $116.37, for a total transaction of $24,437,700.00. The disclosure for this sale can be found here. In the last quarter, insiders bought 8,405 shares of company stock worth $909,004 and sold 614,373 shares worth $70,546,895. 0.11% of the stock is owned by corporate insiders.
NYSE LLY opened at $113.53 on Friday. The company has a fifty day simple moving average of $110.61 and a two-hundred day simple moving average of $112.67. The stock has a market cap of $106.81 billion, a P/E ratio of 20.46, a P/E/G ratio of 1.82 and a beta of 0.16. Eli Lilly And Co has a 12-month low of $101.36 and a 12-month high of $132.13. The company has a current ratio of 1.17, a quick ratio of 0.88 and a debt-to-equity ratio of 4.09.
Eli Lilly And Co (NYSE:LLY) last posted its quarterly earnings results on Wednesday, October 23rd. The company reported $1.48 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $1.43 by $0.05. The business had revenue of $5.48 billion during the quarter, compared to analysts’ expectations of $5.50 billion. Eli Lilly And Co had a net margin of 35.10% and a return on equity of 107.99%. The business’s quarterly revenue was up 3.2% on a year-over-year basis. During the same quarter last year, the company posted $1.39 earnings per share. As a group, sell-side analysts forecast that Eli Lilly And Co will post 5.78 earnings per share for the current year.
The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 10th. Stockholders of record on Friday, November 15th will be paid a $0.645 dividend. The ex-dividend date of this dividend is Thursday, November 14th. This represents a $2.58 dividend on an annualized basis and a dividend yield of 2.27%. Eli Lilly And Co’s payout ratio is currently 46.49%.
Eli Lilly And Co Company Profile
Eli Lilly and Company discovers, develops, manufactures, and markets pharmaceutical products worldwide. The company operates in two segments, Human Pharmaceutical Products and Animal Health Products. It offers endocrinology products for the treatment of diabetes; osteoporosis in postmenopausal women and men; and human growth hormone deficiency and pediatric growth conditions.
Featured Story: How is Preferred Stock Different from Common Stock?
Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly And Co (NYSE:LLY).
Receive News & Ratings for Eli Lilly And Co Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly And Co and related companies with MarketBeat.com's FREE daily email newsletter.